Back to Search Start Over

Clinical Management and Outcomes of Nontuberculous Mycobacterial Infections in Solid Organ Transplant Recipients: A Multinational Case-control Study.

Authors :
López-Medrano F
Carver PL
Rutjanawech S
Aranha-Camargo LF
Fernandes R
Belga S
Daniels SA
Mueller NJ
Burkhard S
Theodoropoulos NM
Postma DF
van Duijn PJ
Arnaiz de Las Revillas F
Pérez Del Molino-Bernal C
Hand J
Lowe A
Bodro M
Vanino E
Fernández-Cruz A
Ramos-Martínez A
Makek MJ
Bou Mjahed R
Manuel O
Kamar N
Calvo-Cano A
Rueda-Carrasco L
Muñoz P
Álvarez-Uría A
Pérez-Recio S
Sabé N
Rodríguez-Álvarez R
Silva JT
Mularoni A
Vidal E
Alonso-Titos J
Del Rosal T
Classen AY
Goss CW
Agarwal M
Mejía-Chew C
Source :
Transplantation [Transplantation] 2024 Jul 25. Date of Electronic Publication: 2024 Jul 25.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Background: The management and outcomes of nontuberculous mycobacterial (NTM) infections in solid organ transplant (SOT) recipients are poorly characterized. We aimed to describe the management and 1-y mortality of these patients.<br />Methods: Retrospective, multinational, 1:2 matched case-control study included SOT recipients aged 12 y old or older diagnosed with NTM infection between January 1, 2008, and December 31, 2018. Controls were matched on transplanted organs, NTM treatment center, and posttransplant survival at least equal to the time to NTM diagnosis. The primary aim was 1-y mortality after NTM diagnosis. Differences between cases and controls were compared using the log-rank test, and Cox regression models were used to identify factors associated with mortality at 12 mo among cases.<br />Results: In 85 patients and 169 controls, the median age at the time of SOT was 54 y (interquartile range, 40-62 y), 59% were men, and the lungs were the most common site of infection after SOT (57.6%). One-year mortality was significantly higher in cases than in controls (20% versus 3%; P < 0.001), and higher mortality was associated with lung transplantation (hazard ratio 3.27; 95% confidence interval [1.1-9.77]; P = 0.034). Median time (interquartile range) from diagnosis to treatment initiation (20 [4-42] versus 11 [3-21] d) or the reduction of net immunosuppression (36% versus 45%, hazard ratio 1.35 [95% CI, 0.41-4.43], P = 0.618) did not differ between survivors and those who died.<br />Conclusions: NTM disease in SOT recipients is associated with a higher mortality risk, especially among lung transplant recipients. Time to NTM treatment and reduction in net immunosuppression were not associated with mortality.<br />Competing Interests: The authors declare no funding or conflicts of interest.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1534-6080
Database :
MEDLINE
Journal :
Transplantation
Publication Type :
Academic Journal
Accession number :
39049076
Full Text :
https://doi.org/10.1097/TP.0000000000005156